Compare RAVE & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | XLO |
|---|---|---|
| Founded | 1958 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 41.8M |
| IPO Year | N/A | 2021 |
| Metric | RAVE | XLO |
|---|---|---|
| Price | $3.35 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 21.6K | ★ 483.5K |
| Earning Date | 02-05-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.18 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | $12,375,000.00 | ★ $31,804,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | $15.93 | ★ N/A |
| Revenue Growth | 1.14 | ★ 588.40 |
| 52 Week Low | $2.01 | $0.51 |
| 52 Week High | $3.75 | $1.70 |
| Indicator | RAVE | XLO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.